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Summary.-Response to endocrine therapy in 51 patients with advanced breast
cancer was compared with the amount of elastosis in histological sections from their
primary tumours. There appeared to be an association between elastosis and re-
sponse: tumours with no elastosis showed a lower rate of response than those with
gross elastosis, indicating that this simple method might provide a useful predictive
index for response to endocrine therapy. In addition, tumours with oestrogen-
receptor activity (a feature associated with a high rate of response) but with no
elastosis were unlikely to respond, suggesting that a combination of the 2 pre-
dictive indices might be more valuable than either taken alone.
CURRENT METHODS for the selection of
patients with advanced breast cancer for
endocrine therapy are limited, because
none provides absolute means of deter-
mining which patients will respond.
Although the absence of oestrogen re-
ceptor activity (RE) in a tumour corre-
lates well with lack of response to endo-
crine therapy, not all patients with
tumours containing RE will respond
(McGuire et al., 1975; Roberts et al., 1978).
Recent studies have indicated that a
histological feature of breast cancer, the
amount of elastosis in the primary
tumour, is associated with menstrual
status (Lundmark, 1972; Masters et al.,
1978), prognosis (Shivas & Douglas, 1972;
Wallgren et al., 1976) and RE (Masters et
al., 1976). These findings suggest that
elastosis is related to endocrine status and
therefore might be ofvalue as a predictive
index for response to endocrine therapy.
The present study tests this hypothesis by
relating elastosis and response ofadvanced
breast cancer to endocrine therapy.
MATERIALS AND METHODS
The amount of elastosis was measured
qualitatively in histological sections from 51
primary breast cancers from patients who
subsequently received endocrine therapy for
metastatic disease. Histological sections were
stained with orcein to demonstrate elastosis.
This stain was compared with the modified
Gomori aldehyde-fuchsin stain previously
used (Shivas & Douglas, 1972; Masters et al.,
1976, 1978) on a series of 30 tumours, and
identical results were obtained by 2
observers. The amount of elastosis was
categorized as follows: 0 indicated that
elastosis was not demonstrable, 1 that it was
present to a small or moderate degree, and 2
that there was a gross degree of elastosis.
The assessments correspond to those of
Shivas & Douglas (1972), in that Category
0 corresponds to Elastica Index 0, Category 1
to Indices + and ++ andCategory2toIndex
+++. Focal deposits of elastica around
malignant cells and ducts lined by malignant
cells, but not the material around blood
vessels and ducts lined by non-neoplastic
epithelium, formed the basis of the assess-
ment. Diffuse elastosis consisting of indi-
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vidual coarse and/or fine fibrils distributed in
an apparently random array was not in-
cluded in the assessment. In the current study
the amount of elastosis was assessed inde-
pendently by 2 observers and, in the small
number of cases in which disagreement
occurred, the slides were re-read and classified
by joint decision. All assessments were made
without knowledge of the patient's history,
treatment or response.
RE was measured in either the primary or
metastatic tumour in 50 of these cases using
the method of King et al. (1977). Tumours
were categorized as RE+ (>5 fmol protein/
ml, detectable) or RE- (<5 fmol protein/ml,
not detectable).
The endocrine treatment given to patients
included oophorectomy (8 patients), oestro-
gens (12 patients), androgens (11 patients),
tamoxifen (13 patients) and hypophysectomy
(7 patients). Response was assessed using the
UICC criteria (Hayward et al., 1977) which
define 4 categories, summarized as follows:
(1) Complete response (CR)-disappear-
ance of all known disease.
(2) Partial response (PR)-50% or more
decrease in the sum ofthe perpendicular axes
of measurable lesions. No new lesions. It is
not necessary for every lesion to have re-
gressed, but no lesion should have progressed.
(3) No change (NC)-lesions unchanged.
(4) Progressive disease (PD). (a) Mixed-
some lesions regress while other progress or
new lesions appear. (b) Failure-progression
of some or all lesions and/or appearance of
new lesions; no lesions regress.
RESULTS
The results are summarized in Tables I
and II. There appears to be an association
between elastosis and response to endo-
crine therapy (see Table I and Fig.). Of
the patients with tumours containing
Category 0 elastosis, 86% failed to show
either complete or partial response to
treatment, compared with 74% and 50%
with Categories 1 and 2 respectively. This
association is even more apparent when
the 6 patients achieving a complete re-
sponse are considered as a separate group.
While only 6 of the 51 tumours studied
TABLE I.-The relationship between the
amount of elastosis (categorized as 0, 1
or 2) and the response (assessed by UICC
criteria) of advanced breast cancer to
endocrine therapy
Response to therapy
Objective regression
Complete response
Partial response
No change
Progressive disease
Total
Elastosis category
0 1 2
2 8 3
0 3 3
2 5 0
3 5
9 18
14 31
1
2
6
El Progressive Disease
El No change
U Partial orcomplete response
.,.
......
1
Elastosis Category
FIG.- The relationship between the amount of elastosis (categorized as 0, 1 or 2) and the response
(assessed by JICC criteria) to endocrine therapy of 51 patients with advanced breast cancer.
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TABLE II.-Combined RE (categorized as +
or -) and elastosis (categorized as 0, 1
or 2) as a predictive index for response
(assessed by UICC criteria) of advanced
breast cancer to endocrine therapy
Responders
RE Elastosis (PR+CR)
+ 0 1/8 (13%)
1 8/19 (42%)
2 3/5 (60%)
0 1/6 (17%)
1 1/11 (9%)
2 0/1 (0%)
showed Category 2 elastosis, 3 of these
achieved a complete response. This finding
is statistically highly significant (P<
0.005).
The result of combining elastosis assess-
ment with RE to produce a single pre-
dictive index for response is shown in
Table II. Of the RE+ tumours, only 13%
with Category 0 elastosis responded to
treatment, compared with 42% and 60%
respectively with Categories 1 and 2.
DISCUSSION
The results indicate that the assessment
of elastosis in primary breast cancers
might be used in the selection of patients
receiving endocrine therapy for metastatic
disease (Table I). First, in relation to
patients who will not respond to endo-
crine therapy, in this small series only
2/14 patients (14%) with Category 0
elastosis in their tumours showed any
objective response. Second, with respect
to the patients who will respond to endo-
crine therapy, 3/6 patients (50%) with
Category 2 elastosis achieved a complete
response.
A combination of RE and elastosis
assessments provides a better predictive
index for response to endocrine therapy
than either feature taken alone. The re-
sults indicate that RE+ tumours with
Category 0 elastosis are unlikely torespond
to therapy (Table II).
The importance of using objective
criteria to assess tumour response is well
recognized. This preliminary study is
based on data from 51 patients. Although
more patients were initially included in
this series, a large number had to be ex-
cluded either because the primary tumour
was not available or because objective
assessment using UICC criteria (Hayward
et al., 1977) was not possible. It is hoped
that this preliminary communication will
encourage further investigation of elast-
osis as a predictive index for the response
of advanced breast cancer to endocrine
therapy.
Several authors have discussed methods
of grading elastosis (Lundmark, 1972;
Shivas & Douglas, 1972; Azzopardi &
Laurini, 1974), but these assessments are
not comparable because of differences in
the sites of elastica included in the
grading. For example, in contrast to the
present study, Azzopardi & Laurini (1974)
included increased elastosis around ducts
lined by non-neoplastic epithelium and
vasculature in their assessment. Further
studies will be necessary to determine
whether such elastosis is of significance in
relation to response to endocrine therapy.
The reported incidence of elastosis in
breast tumours varies from 45 to 88%
according to the type of tumour ex-
amined and the method of assessment
(Bonser et al., 1961; Lundmark, 1972;
Azzopardi & Laurini, 1974; Fisher et al.,
1975). Elastosis is uncommon in mucoid
and medullary carcinomas (Azzopardi &
Laurini, 1974). However, there is no
evidence that these relatively uncommon
histological types oftumour are less likely
to respond to endocrine therapy. Thus the
absence of elastosis in certain histological
types of carcinoma may not be of pre-
dictive significance.
Previous studies have shown a positive
association between elastosis and RE
(Masters et al., 1976, 1978). In the present
study a similar trend was found. Of the
tumours with Category 0 elastosis, 8/14
(57%) contained RE, compared with 19/30
(63%) and 5/6 (83%) of tumours with
Categories 1 and 2 elastosis respectively.
The amount of elastosis in breast
cancers is related to age (Lundmark, 1972)
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and menstrual status (Masters et al., 1978).
A larger series of cases will need to be
studied to determine whether allowance
for these factors is necessary. Patients in-
cluded in this study received a variety of
different treatments. Further studies will
also be necessary to determine whether
elastosis is of value as a predictive index
for all forms of endocrine therapy.
Assessment of elastosis is simple and
rapid and does not require additional
tissue or expertise. It could be included
readily in routine pathology reports or
could be performed retrospectively on
tissue obtained from the primary tumour.
It is concluded from this small series
that elastosis might be of some value for
predicting response of advanced breast
cancer to endocrine therapy, and could be
used to improve the predictive value of
RE determination.
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